BTG Share News (BTG)

Healthcare group BTG said it expected annual revenue to be "slightly" higher than indicated earlier this year.The FTSE 250 group said expected revenue for the year ended 31 March would be above the previous guidance it provided of £345m to £360m, including revenue from the PneumRx acquisition it completed in January.Acquisition-related accounting adjustments and costs of approximately £8m, together with the previously reported one-off expenses of about £8m relating to the settlement of the CroFab litigation are expected to result in total exceptional costs for the year of approximately £16m.In a pre-close statement on Thursday, the London-listed company said it expected revenue to grow strongly in the current financial year to between £410m and £440m.BTG added that the launch of its Varithena treatment was continuing in the US, where 300 physicians had completed the required online training, with over 140 of these having treated patients and another 60 in the process of scheduling patients for treatment.The healthcare group said the treatment was expected to add between $15m (£10.1m) and $25m to revenue for the 2016 financial year.Analysts at Shore Capital praised the group for its "laudable" strategy, which"should enable the company to best deliver to shareholders the greatest return in relatively niche areas where self-marketing is a feasible proposition."The brokerage reiterated its 'buy' rating on the stock.BTG shares were up 6.10% to 782.50p at 09:00 on Thursday.